The Efficacy of Ivermectin in Larger Doses in COVID-19 Treatment

Sponsor

Tanta University (Other)

Overall Status

Recruiting

CT.gov ID

NCT04351347

Collaborator

(none)

300

Enrollment

Location

Arms

125.5

Anticipated Duration (Months)

2.4

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Efficacy of Ivermectin in larger doses in COVID-19 treatment

Condition or Disease	Intervention/Treatment	Phase
COVID	Drug: Ivermectin	Phase 2/Phase 3

Detailed Description

Clinical Study Evaluating the Efficacy of Ivermectin in higher doses in COVID-19 treatment

Study Design

Study Type:

Interventional

Anticipated Enrollment :

300 participants

Allocation:

Randomized

Intervention Model:

Parallel Assignment

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

Clinical Study Evaluating the Efficacy of Ivermectin in Larger Doses in COVID-19 Treatment

Actual Study Start Date :

Jun 16, 2020

Anticipated Primary Completion Date :

Dec 1, 2030

Anticipated Study Completion Date :

Dec 1, 2030

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Ivermectin Ivermectin alone in larger doses	Drug: Ivermectin ivermectin
No Intervention: Standard treatment Standard of care treatment

Arm

Intervention/Treatment

Experimental: Ivermectin

Ivermectin alone in larger doses

Drug: Ivermectin

ivermectin

No Intervention: Standard treatment

Standard of care treatment

Outcome Measures

Primary Outcome Measures

Number of patients with improvement or died [1 month]
The number of patients with improvement or death

Eligibility Criteria

Criteria

Ages Eligible for Study:

N/A and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Patients with covid 19

Exclusion Criteria:

Allergy or side effects to treatment

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Tanta University	Tanta		Egypt	35111

Sponsors and Collaborators

Tanta University

Investigators

Principal Investigator: sherief Abd-Elsalam, Ass. Prof., Tanta University - Faculty of Medicine

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

Responsible Party:

Sherief Abd-Elsalam, Ass. Prof. Tropical Medicine, Tanta University

ClinicalTrials.gov Identifier:

NCT04351347

Other Study ID Numbers:

ivermecin covid

First Posted:

Apr 17, 2020

Last Update Posted:

Mar 10, 2021

Last Verified:

Mar 1, 2021

Individual Participant Data (IPD) Sharing Statement:

Plan to Share IPD:

Studies a U.S. FDA-regulated Drug Product:

Studies a U.S. FDA-regulated Device Product:

Additional relevant MeSH terms:

Ivermectin

Study Results

No Results Posted as of Mar 10, 2021